Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus METHYLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus METHYLIN.
AMPHETAMINE SULFATE vs METHYLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
Methylphenidate is a central nervous system stimulant. It blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
10 mg orally twice daily, administered 4-6 hours apart; doses may be adjusted in 5-10 mg increments weekly up to 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
2-4 hours (short elimination half-life, requiring multiple daily dosing; immediate-release: 3-4 hours, extended-release: 3-6 hours)
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Renal: 90% (mainly as metabolites, 30-50% as unchanged drug); fecal: <1%
Category D/X
Category C
CNS Stimulant
CNS Stimulant